GoodRx Holdings (GDRX) Interest Expenses (2019 - 2026)

GoodRx Holdings has disclosed Interest Expenses across 8 years of filings, most recently posting $9.8 million for Q1 2026.

• Interest Expenses for Q1 2026 came in at $9.8 million, down 8.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $41.7 million (down 14.71% YoY), and the FY2025 annual result was $42.6 million, down 19.49% from the prior year.
• Interest Expenses came in at $9.8 million for Q1 2026 at GoodRx Holdings, down from $10.4 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $14.8 million in Q4 2023 to a low of $5.9 million in Q1 2022.
• The 5-year median for Interest Expenses is $11.4 million (2024), against an average of $11.5 million.
• Across the five-year window, Interest Expenses surged 123.77% in 2023 and slipped 27.31% in 2025, its largest moves.
• GoodRx Holdings' Interest Expenses stood at $11.9 million in 2022, then advanced by 24.26% to $14.8 million in 2023, then declined by 23.37% to $11.4 million in 2024, then fell by 8.41% to $10.4 million in 2025, then declined by 6.11% to $9.8 million in 2026.
• The last three Interest Expenses figures came in at $9.8 million (Q1 2026), $10.4 million (Q4 2025), and $10.8 million (Q3 2025), per Business Quant data.